Recent Improvements in Genomic and Transcriptomic Understanding of Anaplastic and Poorly Differentiated Thyroid Cancers

Endocrinol Metab (Seoul). 2020 Mar;35(1):44-54. doi: 10.3803/EnM.2020.35.1.44.

Abstract

Anaplastic thyroid cancer (ATC) is a lethal human cancer with a 5-year survival rate of less than 10%. Recently, its genomic and transcriptomic characteristics have been extensively elucidated over 5 years owing to advance in high throughput sequencing. These efforts have extended molecular understandings into the progression mechanisms and therapeutic vulnerabilities of aggressive thyroid cancers. In this review, we provide an overview of genomic and transcriptomic alterations in ATC and poorly-differentiated thyroid cancer, which are distinguished from differentiated thyroid cancers. Clinically relevant genomic alterations and deregulated signaling pathways will be able to shed light on more effective prevention and stratified therapeutic interventions for affected patients.

Keywords: Genome; High-throughput nucleotide sequencing; Thyroid carcinoma, anaplastic; Thyroid neoplasms; Transcriptome.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adenocarcinoma / genetics
  • Adenocarcinoma / pathology*
  • Adenocarcinoma, Follicular / genetics
  • Adenocarcinoma, Follicular / pathology*
  • Animals
  • Biomarkers, Tumor / genetics*
  • Carcinoma, Papillary / genetics
  • Carcinoma, Papillary / pathology*
  • Computational Biology
  • Disease Progression
  • Genomics / methods*
  • Humans
  • Mutation
  • Thyroid Neoplasms / genetics
  • Thyroid Neoplasms / pathology*
  • Transcriptome*

Substances

  • Biomarkers, Tumor